# A Study of Combination Therapy in Patients With Resectable Liver Cancer

> **NCT07684040** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Affiliated Hospital of Guangdong Medical University** · enrollment: 68 (estimated)

## Conditions studied

- Liver Cancer (Primary and Metastatic)

## Interventions

- **DRUG:** Hepatic Arterial Infusion Chemotherapy Combined with Adebrelimab Plus Rivoceranib

## Key facts

- **NCT ID:** NCT07684040
- **Lead sponsor:** Affiliated Hospital of Guangdong Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08-01
- **Primary completion:** 2030-07-01
- **Final completion:** 2030-10-01
- **Target enrollment:** 68 (ESTIMATED)
- **Last updated:** 2026-07-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07684040

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07684040, "A Study of Combination Therapy in Patients With Resectable Liver Cancer". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07684040. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*